PROTAC BCR-ABL Degrader-2
PROTAC BCR-ABL Degrader-2 is a selective Bcr-AblT315 PROTAC degrader with a DC50 of 108.7 nM in Ba/F3 Bcr-AblT315I cells. PROTAC BCR-ABL Degrader-2 exhibits the most potent degradation efficacy with DR of 69.89% and 94.23% at 100 and 300 nM, respectively. PROTAC BCR-ABL Degrader-2 demonstrates high plasma exposure, and induces significant tumor regression and induces tumor cell apoptosis with a good safety profile in vivo. PROTAC BCR-ABL Degrader-2 can be used for chronic myeloid leukemia (CML) research.
(Pink: Bcr-Abl ligand (HY-15666); Blue: Cereblon ligand (HY-10984); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 2703834-25-5
- Formula: C48H46F3N9O6
- Molecular Weight:901.93
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All PROTACs Isoforms
More
Biological Activity
PROTAC BCR-ABL Degrader-2 (Compound 7o) (72 h) against K562, Ba/F3 Bcr-AbllT315I and Ba/F3 Bcr-AblWT with IC50s of 7.7, 26.8 and 4.2 nM[1].
PROTAC BCR-ABL Degrader-2 (0-300 nM) significantly decreases the level of Bcr-AblT315I protein with a DC50 = 108.7 nM in Ba/F3 Bcr-AblT315I cells[1].
PROTAC BCR-ABL Degrader-2 (0-300 nM, 0-48 h) induces Bcr-AblT315I protein level mediated by CRBN E3 ubiquitin pathway while appeared a “hook” effect in Bcr-AbllT315I cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Ba/F3 Bcr-AblT315I and K562 cells
-
Concentration:100 nM
-
Incubation Time:0, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 h
-
Result:Caused the degradation of Bcr-AblT315I protein in a time-dependent manner.
Reduced Bcr-AblT315I protein level substantially after 6h treatment while appeared a “hook” effect during 8-10h treatment.
Observed the maximum degradation after24h treatment.
Displayed a different trend for reducing Bcr-AblWT in K562cells with substantially reduction after 36h treatment (this different might be associated with the different states of E3 ligase in Ba/F3Bcr-AblT315I and K562 cells.).
-
Cell Line:MG132 (HY-13259) (20 ) Ba/F3 Bcr-AblT315I cells
-
Concentration:100 and 300 nM
-
Incubation Time:24 h
-
Result:Induced Bcr-AblT315I degradation rescuing by MG132.
PROTAC BCR-ABL Degrader-2 (10-20 mg/kg, i.p., once every two days for 14 days) displays significant anti-cancer activity and safety in the Ba/F3 Bcr-AblT315I mice xenograft models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ba/F3 cells expressing Bcr-AblT315I (2 x 106 cells/0.1 mL) induced-CB17-SCID mice [1]
-
Dosage:10 or 20 mg/kg
-
Administration:i.p., once every two days for 14 days
-
Result:Obviously sup pressed the growth of Ba/F3 Bcr-AblT315I xenograft tumor with a tumor growth inhibition (TGI) value of 90.8% at the dose of 20 mg/kg.
Induced the Bcr-AblT315I degradation and apoptosis.
Resulted no mortality or significant body weight loss.
Chemical Information
-
CAS No. 2703834-25-5
-
Molecular Weight 901.93
-
Formula C48H46F3N9O6
-
SMILES
O=C(C1=CC=C(C)C(C#CC2=CC3=C(NN=C3)N=C2)=C1)NC4=CC=C(CN5CCN(CCCCCCC(NC6=CC=CC(C(N7C8C(NC(CC8)=O)=O)=O)=C6C7=O)=O)CC5)C(C(F)(F)F)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Jiang L, et al. Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. Acta Pharm Sin B. 2021 May;11(5):1315-1328. [Content Brief]
[2]. Chen X, et al. Mighty mini-PROTACs: an emerging class of degraders. Eur J Med Chem. 2026 Jan 5;301:118202. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz